<DOC>
	<DOCNO>NCT02059252</DOCNO>
	<brief_summary>SmartMatrix™ single layer dermal replacement scaffold full thickness skin replacement . The scaffold consist porous matrix cross-linked human fibrin plus alginate design optimised facilitate wound closure heal cellular ingres rapid growth new blood vessel . This proof concept study involve patient surgical wound result excision basal cell carcinoma ( BCC ) squamous cell carcinoma SCC ) .</brief_summary>
	<brief_title>Safety , Tolerability Performance SmartMatrix Dermal Replacement Scaffold</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>Male female , least 18 year age Suspected histologically proven BCC SCC Suspected histologically proven BCC SCC ≥1cm ≤3cm diameter either leg Expected defect follow surgery ≥3cm , ≤6cm diameter Patient authorise representative able comprehend sign Informed Consent prior enrolment study Aged &lt; 18 year age Pregnant lactating female Skin lesion &gt; 4cm diameter size result postsurgical defect &gt; 6cm diameter Lesion locate joint , i.e . ankle knee Patient smoker Diabetic patient Patients diagnosed peripheral vascular disease venous stasis Patients receive regular systemic steroid Patients immunocompromised ( either acquire congenital ) Patients know coagulopathy ( either acquire congenital ) include patient aspirin antiplatelet therapy Patients receive radiotherapy treatment area treat Smart Matrix Concurrent participation another experimental intervention drug study Unwilling unable provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>